* Disease evolves over many years along multiple pathways * Diversity helps explain why disease so hard to treat * Research highlights need for earlier detection By Ben Hirschler LONDON, Oct 9 (Reuters) - Lung cancer can lie dormant for more than 20 years before turning de
** Shares in French biotechnology company Innate Pharma jump 8 pct as Citi initiates with a "buy" recommendation and 10 euros/share PT. ** French biotech this year: http://link.reuters.com/kag23w ** Innate tipped as a rarity in Europe -- a publicly listed immuno-oncology company with
Woodford Investment Management has added to its core holdings in British American Tobacco and G4S in its portfolio but announced it had sold down its stake in Reckitt Benckiser. Speaking about its decision to sell stakes in the multinational consumer goods company, which had been part of the fund fo
Poor economic data was weighing on UK stocks on Tuesday, with decent gains in the mining sector offset by falls from airlines and pharmaceuticals. The FTSE 100 was trading 0.6% lower at 6,522 by around midday. Nervousness ahead of the start of third-quarter earnings season in the States was also ca
African Minerals: Canaccord Genuity lowers target price from 20p to 15p with a hold recommendation. Aggreko: Exane initiates with a target price of 1500p and an underperform rating. Amec: Liberum Capital cuts target price from 1035p to 908p staying with its sell recommendation. Antofagasta: Canacc
Strong gains in the UK mining sector weren't enough to keep London's FTSE 100 from slipping into the red on Tuesday morning. Indices across Europe were tracking a weak finish on Wall Street and a mixed performance on Asian markets overnight. The FTSE 100 was trading 0.6% lower at 6,526 within the o
LONDON, Oct 6 (Reuters) - AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. The endorsement comes in an updated guideline from the American Heart Asso
(Adds details, background) By Deena Beasley Oct 5 (Reuters) - Medical equipment supplier Becton Dickinson & Co has agreed to buy CareFusion Corp , a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcar
(Adds background, CEO comments) By Deena Beasley Oct 5 (Reuters) - Medical equipment supplier Becton Dickinson & Co has agreed to buy CareFusion Corp , a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar heal
** Eighth-largest shareholder Axa Investment Managers adding to stake in biotech firm BTG Group, backing stock to enter FTSE 100. ** Nigel Thomas, manager of the Â£4.5 bln Axa Framlington UK Select Opportunities fund, increasing the fund's exposure to healthcare through BTG and AstraZeneca.
(Adds share move, analyst forecast) By Bill Berkrot Oct 1 (Reuters) - An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday.
By Bill Berkrot Oct 1 (Reuters) - A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday. In the 12-week study involving